Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 10/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 9/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792811 | 0.96 | HTR2A (0.53) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL6221565 | 0.91 | HTR2A (0.50) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL6220391 | 0.85 | HTR1A (0.54) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL5794638 | 0.81 | HTR2A (0.51) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL5763496 | 0.80 | HTR2A (0.51) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL5767115 | 0.79 | HTR2A (0.57) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL6400640 | 0.78 | HTR7 (0.52) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL5795679 | 0.78 | HTR1A (0.62) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL5764221 | 0.78 | HTR1A (0.62) | HTR2AHTR1AKCNH2DRD2HTR7 | |
| SCHEMBL6404304 | 0.77 | DRD2 (0.52) | HTR2AHTR1AKCNH2DRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | HTR2A 16/4885HTR1A 17/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.